cysteamine has been researched along with Parkinson Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q; Quan, J; Wang, X; Xu, B; Xu, Z | 1 |
| Choi, SY; Choi, YJ; Eum, WS; Han, KH; Kim, DS; Kim, DW; Lee, KW; Lee, LR; Park, J; Park, JK; Shin, MJ; Song, Y; Yeo, EJ; Yeo, HJ | 1 |
| Cicchetti, F; David, LS; Denis, HL; Siddu, A | 1 |
| Ahn, EH; Cho, SW; Choi, SY; Eom, SA; Eum, WS; Jo, HS; Kim, DS; Kim, DW; Kim, HR; Kim, SM; Park, J; Shin, MJ; Woo, SJ | 1 |
| Cheng, H; Davis, JJ; Lehr, J; Patil, AV; Xu, Q | 1 |
| Chang, JC; Chen, YH; Cheng, FC; Chuang, CS; Kuo, SJ; Liu, CS; Liu, KH; Su, HL; Wei, YH; Wu, SL | 1 |
| Cicchetti, F; Gibrat, C | 1 |
| Cho, SW; Cho, YS; Choi, SY; Eom, SA; Eum, WS; Hwang, HS; Kim, DS; Kim, DW; Kim, YN; Lee, SH; Park, J; Sohn, EJ; Yoon, GH | 1 |
| Schipper, HM | 1 |
| Vécsei, L; Widerlöv, E | 1 |
4 review(s) available for cysteamine and Parkinson Disease
| Article | Year |
|---|---|
Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial.
Topics: Clinical Trials as Topic; Cysteamine; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease | 2019 |
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Topics: Animals; Cystamine; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Humans; Huntington Disease; Mice; Mice, Transgenic; Molecular Targeted Therapy; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Radiation-Protective Agents | 2011 |
Brain iron deposition and the free radical-mitochondrial theory of ageing.
Topics: Aging; Alzheimer Disease; Animals; Astrocytes; Brain; Catechols; Central Nervous System Diseases; Cysteamine; Free Radicals; Gene Expression; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Iron; Membrane Proteins; Mitochondria; Models, Biological; Oxidative Stress; Parkinson Disease; Peroxidase; Superoxide Dismutase | 2004 |
Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system.
Topics: Alcoholism; Animals; Central Nervous System; Central Nervous System Diseases; Cerebrovascular Disorders; Cysteamine; Humans; Pantetheine; Parkinson Disease | 1990 |
6 other study(ies) available for cysteamine and Parkinson Disease
| Article | Year |
|---|---|
N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Glutamate-Cysteine Ligase; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2022 |
PEP-1-GLRX1 Reduces Dopaminergic Neuronal Cell Loss by Modulating MAPK and Apoptosis Signaling in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Line; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Regulation; Glutaredoxins; Humans; Male; MAP Kinase Signaling System; Mice; Parkinson Disease; Peptides; Substantia Nigra | 2021 |
PEP-1-PEA-15 protects against toxin-induced neuronal damage in a mouse model of Parkinson's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Cysteamine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Peptides; Phosphoproteins; Reactive Oxygen Species; Recombinant Fusion Proteins; Transduction, Genetic | 2014 |
Graphene oxide interfaces in serum based autoantibody quantification.
Topics: alpha-Synuclein; Autoantibodies; Biosensing Techniques; Cysteamine; Electrochemical Techniques; Gold; Graphite; Humans; Limit of Detection; Microelectrodes; Parkinson Disease | 2015 |
Allogeneic/xenogeneic transplantation of peptide-labeled mitochondria in Parkinson's disease: restoration of mitochondria functions and attenuation of 6-hydroxydopamine-induced neurotoxicity.
Topics: Animals; Calbindins; Cell Transplantation; Cysteamine; Dopaminergic Neurons; Female; Humans; Mitochondria; Oxidative Stress; Oxidopamine; Parkinson Disease; PC12 Cells; Peptides; Rats; Rats, Sprague-Dawley; Substantia Nigra; Transplantation, Heterologous; Transplantation, Homologous | 2016 |
PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Cysteamine; Disease Models, Animal; DNA Fragmentation; Dopaminergic Neurons; Genetic Vectors; Humans; Mice; MPTP Poisoning; Oxidative Stress; Parkinson Disease; Peptides | 2012 |